Literature DB >> 17935123

Assessment of causes of death in a prostate cancer screening trial.

Tuukka Mäkinen1, Pekka Karhunen, Jussi Aro, Jorma Lahtela, Liisa Määttänen, Anssi Auvinen.   

Abstract

Accurate assessment of the causes of death is crucial for a conclusive evaluation of the ongoing prostate cancer screening trials. Here, we report the validity of the official causes of death as compared with an independent expert review in the Finnish prostate cancer screening trial. Because nearly 80,000 men were involved, death-cause evaluation was restricted to men diagnosed for prostate cancer. Medical charts were retrieved and the cause of death was assigned by an expert review panel for all deaths among men with prostate cancer during the study period, 1996-2003. The panel decision was compared with both death certificates and the official causes of death as assigned by Statistics Finland. Of a total of 315 deaths, the review panel attributed 127 (41%) to prostate cancer and 184 (59%) to other causes, the corresponding figures in death certificates being 124 (40%) and 187 (60%). Four cases were excluded because of insufficient information. The death-certificate data were in agreement with the panel's assessment in 305 out of 311 cases (overall agreement 97.7%, kappa = 0.95). The overall agreement between the official causes of death and the panel's decision was 97.4% (304/311, kappa = 0.95). The sensitivity of the certificates in identifying prostate cancer deaths was 96.1% (panel as golden standard). Correspondingly, specificity was 98.9%. The official causes of death thus provide an accurate means for evaluating disease-specific mortality in a large population-based prostate-cancer screening trial in Finland. Copyright 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2008        PMID: 17935123     DOI: 10.1002/ijc.23126

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

1.  Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening.

Authors:  Anssi Auvinen; Sue M Moss; Teuvo L J Tammela; Kimmo Taari; Monique J Roobol; Fritz H Schröder; Chris H Bangma; Sigrid Carlsson; Gunnar Aus; Marco Zappa; Donella Puliti; Louis J Denis; Vera Nelen; Maciej Kwiatkowski; Marco Randazzo; Alvaro Paez; Marcos Lujan; Jonas Hugosson
Journal:  Clin Cancer Res       Date:  2015-08-19       Impact factor: 12.531

2.  Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Marco Zappa; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Liisa Määttänen; Hans Lilja; Louis J Denis; Franz Recker; Alvaro Paez; Chris H Bangma; Sigrid Carlsson; Donella Puliti; Arnauld Villers; Xavier Rebillard; Matti Hakama; Ulf-Hakan Stenman; Paula Kujala; Kimmo Taari; Gunnar Aus; Andreas Huber; Theo H van der Kwast; Ron H N van Schaik; Harry J de Koning; Sue M Moss; Anssi Auvinen
Journal:  Lancet       Date:  2014-08-06       Impact factor: 79.321

3.  A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale.

Authors:  Anssi Auvinen; Antti Rannikko; Kimmo Taari; Paula Kujala; Tuomas Mirtti; Anu Kenttämies; Irina Rinta-Kiikka; Terho Lehtimäki; Niku Oksala; Kim Pettersson; Teuvo L Tammela
Journal:  Eur J Epidemiol       Date:  2017-07-31       Impact factor: 8.082

4.  Do we really know the cause of death of the very old? Comparison between official mortality statistics and cohort study classification.

Authors:  Annick Alpérovitch; Marion Bertrand; Eric Jougla; Jean-Sébastien Vidal; Pierre Ducimetière; Catherine Helmer; Karen Ritchie; Gérard Pavillon; Christophe Tzourio
Journal:  Eur J Epidemiol       Date:  2009-09-01       Impact factor: 8.082

5.  Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial – lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer).

Authors:  Naomi J Williams; Elizabeth M Hill; Siaw Yein Ng; Richard M Martin; Chris Metcalfe; Jenny L Donovan; Simon Evans; Laura J Hughes; Charlotte F Davies; Freddie C Hamdy; David E Neal; Emma L Turner
Journal:  BMC Med Res Methodol       Date:  2015-01-23       Impact factor: 4.615

6.  Non-Steroidal Anti-Inflammatory Drugs and Cancer Death in the Finnish Prostate Cancer Screening Trial.

Authors:  Thea Veitonmäki; Teemu J Murtola; Kirsi Talala; Kimmo Taari; Teuvo Tammela; Anssi Auvinen
Journal:  PLoS One       Date:  2016-04-21       Impact factor: 3.240

7.  Impact of cause of death adjudication on the results of the European prostate cancer screening trial.

Authors:  Stephen D Walter; Harry J de Koning; Jonas Hugosson; Kirsi Talala; Monique J Roobol; Sigrid Carlsson; Marco Zappa; Vera Nelen; Maciej Kwiatkowski; Álvaro Páez; Sue Moss; Anssi Auvinen
Journal:  Br J Cancer       Date:  2016-11-17       Impact factor: 7.640

8.  Cancer mortality does not differ by antiarrhythmic drug use: A population-based cohort of Finnish men.

Authors:  Kalle J Kaapu; Lauri Rantaniemi; Kirsi Talala; Kimmo Taari; Teuvo L J Tammela; Anssi Auvinen; Teemu J Murtola
Journal:  Sci Rep       Date:  2018-07-09       Impact factor: 4.379

9.  Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committee.

Authors:  Emma L Turner; Chris Metcalfe; Jenny L Donovan; Sian Noble; Jonathan A C Sterne; J Athene Lane; Eleanor I Walsh; Elizabeth M Hill; Liz Down; Yoav Ben-Shlomo; Steven E Oliver; Simon Evans; Peter Brindle; Naomi J Williams; Laura J Hughes; Charlotte F Davies; Siaw Yein Ng; David E Neal; Freddie C Hamdy; Peter Albertsen; Colette M Reid; Jon Oxley; John McFarlane; Mary C Robinson; Jan Adolfsson; Anthony Zietman; Michael Baum; Anthony Koupparis; Richard M Martin
Journal:  Br J Cancer       Date:  2016-06-02       Impact factor: 7.640

10.  Digoxin and prostate cancer survival in the Finnish Randomized Study of Screening for Prostate Cancer.

Authors:  Kalle J Kaapu; Teemu J Murtola; Kirsi Talala; Kimmo Taari; Teuvo Lj Tammela; Anssi Auvinen
Journal:  Br J Cancer       Date:  2016-10-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.